checkAd

     121  0 Kommentare RenovaCare Awarded New Patents Allowing Greater Versatility of SkinGun; Sterility in Field Environments; Spray Solutions to Now Include Targeted Cells, Drugs or Hormones - Seite 2

    About RenovaCare
    RenovaCare, Inc. is developing new generation autologous stem cell therapies for the regeneration of human organs and tissues. The Company’s initial product under development targets the body’s largest organ, the skin. The Company’s flagship technology, the CellMist System, renders single-cell suspensions of tissue-specific pluripotent cells from donor tissues through sequential protease digestions. The RenovaCare CellMist System facilitates rapid healing of wounds or other afflicted tissues when applied topically as a gentle cell mist using the patented RenovaCare SkinGun. The Company’s SkinGun is used to spray a liquid suspension of a patient’s stem cells – the CellMist Solution – on to wounds.

    Development for next-generation biomedical technologies and devices for addressing unmet medical needs and commercialization is taking place at the RenovaCare R&D Innovation Center, located at StemCell Systems in Berlin, Germany. The Innovation Center houses dedicated RenovaCare cell biology laboratories; additional engineering, fabrication, prototyping and performance testing facilities; and product design studios for medical devices and biomedical products. Experienced contract bioengineers, cell biologists, and support staff work under the direction of a team of MD-PhDs who are experts in regenerative medicine, new product development, and clinical translation.

    RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the Company’s planned or filed submissions to the U.S. Food and Drug Administration will be accepted or cleared by the FDA.

    For additional information, please call Amit Singh at: 1-888-398-0202 or visit: https://renovacareinc.com

    To receive future press releases via email, please visit:
    https://renovacareinc.com/investors/register/
    Follow us on LinkedIn: https://www.linkedin.com/company/renovacare-inc-/
    Follow us on Twitter: https://twitter.com/RenovaCareInc
    Follow us on Facebook: https://www.facebook.com/renovacarercar

    Social Media Disclaimer
    Investors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first.

    Seite 2 von 4



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    RenovaCare Awarded New Patents Allowing Greater Versatility of SkinGun; Sterility in Field Environments; Spray Solutions to Now Include Targeted Cells, Drugs or Hormones - Seite 2 ROSELAND, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) - RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today …